Abstract
In patients with respiratory failure, almitrine causes an increase in arterial O2 partial pressure (paO2) by stimulating peripheral chemoreceptors. Since such patients often require long-term O2 therapy inhibiting peripheral chemoreceptor activity, the effect on arterial blood gases by almitrine (100 mg orally) and increasing amounts of nasally supplied O2 was studied. In ten patients with severe chronic airways obstruction and pulmonary emphysema, almitrine produced a mean increase of paO2 by 5.2 mm Hg both while breathing normal air and during nasal administration of O2 (0.5-2.0 l/min), whereas paCO2 levels remained constant. In 4 patients with pulmonary fibrosis almitrine did not change the paO2. These results show that patients with chronic airways obstruction and pulmonary emphysema respond to a single dose of 100 mg almitrine by an increase of paO2 equivalent to that achieved by administering 1.0 l/min of O2 via the nose.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.